Patents by Inventor Kevin D. Cooper

Kevin D. Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
    Patent number: 6764681
    Abstract: Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: July 20, 2004
    Assignees: Biogen, Inc., The Regents of University of Michigan
    Inventors: Barbara P. Wallner, Kevin D. Cooper
  • Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
    Publication number: 20040136987
    Abstract: Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
    Type: Application
    Filed: February 13, 2004
    Publication date: July 15, 2004
    Applicants: Biogen, Inc., a Massachusetts Corporation, The Regents of the University of Michigan, Ann Arbor, Michigan Corporation
    Inventors: Barbara P. Wallner, Kevin D. Cooper
  • Methods for treating or preventing skin disorders using CD2-binding agents
    Publication number: 20030185824
    Abstract: Methods for treating or preventing an epidermal or dermal disorder, e.g., psoriasis, using a CD2-binding agent, e.g., an inhibitor of the CD2/LFA-3 interaction (e.g., an LFA-3/IgG fusion polypeptide), in combination with an auxiliary agent, e.g., UVB irradiation, are disclosed.
    Type: Application
    Filed: December 26, 2002
    Publication date: October 2, 2003
    Inventors: Akshay K. Vaishnaw, Kevin D. Cooper, Daniel Shrager, Thomas S. McCormick
  • Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
    Publication number: 20020009449
    Abstract: Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
    Type: Application
    Filed: December 5, 2000
    Publication date: January 24, 2002
    Applicant: Biogen, Inc., a Massachusetts corporation
    Inventors: Barbara P. Wallner, Kevin D. Cooper
  • Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
    Patent number: 6162432
    Abstract: Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 19, 2000
    Assignees: Biogen, Inc., The Regents of The University of Michigan
    Inventors: Barbara P. Wallner, Kevin D. Cooper
  • Medical uses of pyruvates
    Patent number: 6086789
    Abstract: A pyruvate compound suitable for cosmetically or dermatologically administering to the skin and for use in treating diabetic ketosis or other medical treatments. The compound includes a pyruvate selected from the group of pyruvate thioester, dihydroxyacetonepyruvate, and an ester of pyruvate and a sugar or a polyol.
    Type: Grant
    Filed: May 12, 1998
    Date of Patent: July 11, 2000
    Assignee: Case Western Reserve University
    Inventors: Henri Brunengraber, Catherine Bomont, France David, Peter T. Hallowell, Kevin D. Cooper, Takhar Kasoumov